



# alfapump® DSR – Potential breakthrough treatment for volume overload in heart failure

Sequana Medical has leveraged its experience and is developing alfapump DSR (Direct Sodium Removal), a convenient and fully implanted system to tackle volume overload in heart failure (HF) patients by removing excess sodium and fluid from the body.

Volume overload in heart failure is a major clinical problem and the leading cause of hospitalisations for patients with heart failure




DSR therapy is Sequana Medical’s proprietary therapy to remove excess sodium and fluid from the body





DSR therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion from the body into a sodium-free solution (DSR infusate)

alfapump DSR leverages on the experience with the alfapump to deliver a fully implanted system for DSR therapy

- 1 Administration of DSR infusate to peritoneal cavity
- 2 Sodium from body diffuses into DSR infusate
- 3 alfapump pumps sodium-rich fluid into the bladder
- 4 Body eliminates excess fluid naturally



Pre-clinical studies demonstrated that DSR therapy is capable of removing large quantities of sodium and fluid



First-in-human study of single dose DSR therapy completed at Yale University and results selected for late-breaking presentation at Heart Failure 2019 on 27 May 2019

Sources: 1: Costanzo et al., J. Am. Coll., 2007; 2: Kilgore et al., 2017; 3: Ross et al., 2010; 4: Weekly recommended intake for humans equals 14 grams (www.cdc.gov)

Important Regulatory Disclaimer: DSR therapy is still in development and any statement regarding safety and efficacy arise from pre-clinical studies and ongoing clinical investigations which have yet to be completed.